Human immunodeficiency virus (HIV)
Human Immunodeficiency Virus (or HIV) is a retrovirus that specifically targets CD4+ T Lymphocyte cells within the immune system of an infected host.
HIV is one of the world's most destructive viruses, and it is estimated that over 35 million people have died from HIV Acquired Immunodeficiency Syndrome (AIDS) since its discovery in the 1980s.
Article by John Renshaw
Expand all
Collapse all
Key Points
- Appropriate management and treatment allows patients who have contracted HIV to live out full lives.
- 97% of those surveyed who receive treatment were virally suppressed.
- Pre-exposure prophylaxis is key to reducing the risk of acquiring HIV in some patients.
- A nurses' role is vital in this process; this includes advocating contraception use, prescribing pre-exposure prophylaxis and encouraging HIV testing.
To view the rest of this content login below; or read sample articles.
Definition
Human Immunodeficiency Virus (or HIV) is a retrovirus that specifically targets CD4+ T Lymphocyte cells within the immune system of an infected host. CD4+ T cells ordinarily formulate the immune response to infection by identifying foreign antigens and then generating an antibody response. These cells quickly become ineffective in patients with HIV, left untreated their immune system deteriorates to become dangerously weak, and they become susceptible to severe opportunistic infections from organisms that would ordinarily be harmless (Touloumi and Hatzakis, 2000; Faulhaber and Aberg, 2009).
The severity of HIV infections can be measured by the amount of virus found within the host, commonly referred to as the ‘viral load’ figure (Terrence Higgins Trust, 2016). Patients with a high viral load have overwhelming HIV infection, which causes rapid CD4+ T cell destruction and a low ‘CD4+ count’ (<350 per microliter) (Faulhaber and Aberg, 2009). HIV is separated into three phases of
To view the rest of this content login below; or read sample articles.
Epidemiology
Each year approximately 6,000 new cases of HIV are diagnosed within the UK, adding to over 100,000 people who are known to be living with HIV (Skingsley et al, 2015; Terrence Higgins Trust, 2015). It is difficult to quantify the exact number of people living with HIV, as almost one in five people who have HIV are unaware of their positive HIV status, which is a public health concern (National Institute for Health and Care Excellence (NICE), 2014; Skingsley et al, 2015).
HIV is most common amongst men who have sex with men (MSM) within the UK, with around 1 in 18 MSM being HIV positive; rising to 1 in 8 within areas of London (National AIDS Trust (NAT), 2014). Black-African people have the second highest incidence, and account for two-thirds of HIV infection within the heterosexual HIV positive population, with incidence of 56 per 1000 aged 15–59 years (Public
To view the rest of this content login below; or read sample articles.
Symptoms
Symptoms associated with primary HIV infection are often severe enough to cause the sufferer to seek health care advice and this provides an opportunity to make an early diagnosis of HIV. Unfortunately, all too often this opportunity is missed and the diagnosis is delayed, exposing the patient to the risks of delayed treatment (Baggaley, 2008). The symptoms of primary HIV infection are vague. They feature in a number of presentations which are relatively benign and commonly seen in primary care. This fact, combined with a lack of awareness of primary HIV infection, most likely explains why early diagnosis is not always made. Signs and symptoms of HIV include:
- fever with rash
- sore throat with swollen glands in the neck
- muscle aches
- joint pains
- headaches
- mucosal ulceration (Boon et al, 2006)
To view the rest of this content login below; or read sample articles.
Diagnosis
Consequences of late diagnosis
Unfortunately many patients with HIV are diagnosed late in infection (Figure 1). In 2009, 34% of patients between the ages of 15 and 49 years and 52% of those over 50 years were diagnosed with a CD4 count below 200 cells/mm3 – well below the recommended threshold for starting antiretroviral treatment (Health Protection Agency, 2010a) and at a level when many would be at risk of opportunistic infection. Many have been living with HIV for years, unaware that they pose a risk to their sexual partners and undiagnosed by the doctors who they have encountered in the interim.
Patients presenting late to care are less likely to mount a good immune response to antiretroviral treatment, more likely to get side effects from treatment and more likely to die of either complications of HIV or other causes (Lucas et al. 2008). Almost all of this
To view the rest of this content login below; or read sample articles.
Treatment
There have been incredible advances in the treatment and prevention of HIV over the years. People living with HIV are living longer, and the age of people living with HIV has risen. The availability of HIV antiretroviral therapy (ART) has seen a disease that once significantly shortened life expectancy evolve into a long-term, chronic condition.
Currently, there is no cure for HIV. But there are a number of drugs available that can slow or halt disease progression. Whilst ART increases life expectancy significantly and decreases the risk of complications associated with premature ageing, it should be noted that morbidity and mortality remain slightly higher than in those people who are uninfected.
The aim of treatment
Treatment aims to prevent the morbidity and mortality that is associated with chronic HIV infection, while at the same time minimising drug toxicity. Treatment should be started before the immune system is permanently damaged, and
To view the rest of this content login below; or read sample articles.
Resources
References
Association of British Insurers. Consumer guide for gay men on HIV and life insurance. 2005. www.abi.org.uk/Publications/ABI_Publications_Consumer_Guide_for_Gay_Men_on_HIV_and_Life_Insurance_db8.aspx (accessed 1 February 2022)
Baylis A, Buck, D, Anderson J et al. The Future of HIV Services in England. Shaping the Response to Changing Needs. 2017. https://www.kingsfund.org.uk/sites/default/files/field/field_publication_file/Future_HIV_services_England_Kings_Fund_April_2017.pdf (accessed 1 February 2022)
British HIV Association and British Association for Sexual Health and HIV. BHIVA/BASHH Guidelines on the use of HIV Pre-exposure Prophylaxis. 2018. https://www.bhiva.org/file/5b729cd592060/2018-PrEP-Guidelines.pdf (accessed 1 February 2022)
Cogan D, Barker D J, Rose, G. (5th Ed). Epidemiology for the Uninitiated. London. BMJ; 2003
Faulhaber J, et al. Acquired Immunodeficiency Syndrome. In: Porth MCMatfin G (eds) Pathophysiology: Concepts of Altered Health States. Chapter 20. 8th edn. Lippincott
To view the rest of this content login below; or read sample articles.